From: The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients
Treatment arm
N
NFκB % change
1-β (power)
Arm A (placebo)
40
+ 5%
–
Arm B (metformin)
−13.5%
90%
Arm C (aspirin)
-13.5%
Arm D (aspirin+metformin)
−55% (~ 3.0-fold the main effects)
80%